CFTR and cystic fibrosis: Additionally, once-daily treatment has the potential for reduced treatment burden and improved adherence, which might lead to better clinical outcomes in people with cystic fibrosis.34 Together, Trial VX21–121-105 and Trials VX20–121-102 and VX20–121-103 (in participants aged ≥12 years)23 provide the most comprehensive initial phase 3 programme to date for a CFTR modulator regimen to assess safety and efficacy and demonstrate the clinical benefit of vanzacaftor–tezacaftor–deutivacaftor for eligible people with cystic fibrosis.